Back

Correction to: Vericiguat and mortality in heart failure and reduced ejection fraction: the VICTOR trial

European Heart Journal

16 April 2026
Organised by: Logo
Read full article
ESC Journals
You may be interested in
thumbnail
Congress Presentation
Guideline-directed medication therapy use among patients with HFrEF receiving vericiguat: comparing findings from a real-world study to clinical trials
29 August 2025
thumbnail
Congress Presentation
Efficacy and safety of vericiguat in patients with HFrEF treated with sacubitril/valsartan: results from the VICTORIA trial
27 August 2021
thumbnail
Congress Session
Pioneering advances in HFrEF management: unlocking the potential of sGC stimulation
18 May 2025
thumbnail
ESC Journals
66 Relative efficacy of sacubitril/valsartan, dapagliflozin and vericiguat: a systematic review and network meta-analysis
17 December 2020

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources